# Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

> **NCT03785249** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Mirati Therapeutics Inc.** · enrollment: 731 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer
- Malignant Neoplastic Disease

## Interventions

- **DRUG:** MRTX849
- **DRUG:** Pembrolizumab
- **DRUG:** Cetuximab
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT03785249
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 731 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785249, "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03785249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*